Deal Positive for Sarepta (SRPT), Summit (SMMT) and DMD Community - Oppenheimer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall St futures muted as bond yields resume climb; Walmart drops after results
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
Sarepta Therapeutics and Summit Enter Into Exclusive License and Collaboration Agreement for European Rights to Summit’s Utrophin Modulator Pipeline for the Treatment of Duchenne Muscular Dystrophy
October 4, 2016 7:00 AM EDTSarepta and Summit collaborate to advance the development of novel therapies for patients with Duchenne muscular dystrophySummit receives $40 million upfront, with potential future ezutromid-related milestone payments totalling up to $522 million plus royaltiesSarepta and Summit to share research and development costsSarepta also receives option for Latin American rights
CAMBRIDGE, Mass. and OXFORD, United Kingdom, Oct. 04, 2016 (GLOBE NEWSWIRE) -- Sarepta Therapeutics (NASDAQ: SRPT) and Summit Therapeutics plc (NASDAQ: SMMT)... More
